Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis

Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program

(2013) Rong Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2012) Christopher G. Azzoli et al.   Journal of Oncology Practice

Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer

(2011) Taroh Satoh et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Chronotherapy and the molecular clock: Clinical implications in oncology☆

(2010) Pasquale F. Innominato et al.   ADVANCED DRUG DELIVERY REVIEWS

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Cisplatin pharmacokinetics in a child receiving peritoneal dialysis

(2010) Judit Sebestyen et al.   PEDIATRIC NEPHROLOGY

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2010) Christopher G. Azzoli et al.   Journal of Oncology Practice

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients

(2008) Pol M. Specenier et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors

(2008) Claire F. Verschraegen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling

(2008) Atilla Altinok et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES